

Time Kill Analyses of Concerning Gram-negative Bacteria (GNB) by Fosfomycin Alone and in Combination with Select Antimicrobial Agents

RK Flamm¹, PR Rhomberg¹, JM Lindley¹, K Sweeney², EJ Ellis-Grosse², HS Sader¹

¹JMI Laboratories, North Liberty, Iowa, USA

²Zavante Therapeutics, Inc. San Diego, California, USA

Background: ZTI-01 (fosfomycin, FOS, for injection) demonstrates broad spectrum activity *in vitro* including multidrug-resistant (MDR) organisms. FOS shows no cross-resistance to other antibiotic classes, and FOS mechanism of action uniquely inhibits an early step in peptidoglycan biosynthesis. Other antibiotic agents in combination with FOS have been proposed to enhance bacterial killing of MDR organisms. Time-kill kinetic analyses (TKK) were performed on select bacteria that demonstrated synergy when tested by checkerboard analysis with FOS and comparator agents.

Methods: Broth microdilution for FOS (Mueller-Hinton broth supplemented with 25 µg/mL glucose-6-phosphate) and comparators was performed before performing TKK. TKK employed MIC multiples for FOS, and ¼ and 1X MIC of select comparators, and combinations of FOS and comparator. TKK were sampled for colony counts at T₀, T₂, T₄, T₈ and T₂₄ hours (h). Two *Klebsiella pneumoniae* isolates (one KPC and one ESBL), two *Pseudomonas aeruginosa* isolates (non-MDR), and one *Acinetobacter baumannii* isolate (MDR) were tested.

Results: FOS was bactericidal when tested against a *K. pneumoniae* (KPC-producer) isolate. A >3 log₁₀ reduction in bacterial growth (colony forming units, CFU) occurred by 4h at 2X MIC. By 24h with FOS (0.5, 1, and 2X MIC), bacterial growth increased approximately 2 log₁₀. Piperacillin-tazobactam (PTZ) at ¼ and 1X MIC showed little inhibitory activity. At 24h, bacterial growth was similar to growth control. FOS at 0.5, 1, and 2X MIC in combination with PTZ (¼ and 1X MIC) showed synergy with approximately a 3.8-4.2 log₁₀ reduction at 4h and a 3.4-5.4 log₁₀ reduction at 24h. FOS (1, 2, 4X MIC) showed a slight decrease (1.4-2.2 log₁₀ CFU) at 4h and by 24h, growth was similar to growth control when tested against an ESBL-producing *K. pneumoniae* isolate. For ceftazidime (CAZ) at ¼ and 1X MIC, there was a slight decrease (0.9-2.1 log₁₀ CFU) by 4-8h, and at 24h CFU were similar to growth control. FOS (1, 2, and 4X MIC) in combination with CAZ showed synergy with a 3.8-4.3 log₁₀ reduction by 8h (1X CAZ MIC) and at least a 5.1 log₁₀ reduction at 24h (1/4 and 1X CAZ MIC). FOS activity was shown to be synergistic at 24h when tested at 2, 4 and 8X MIC with either ¼ or 1X CAZ MIC (*P. aeruginosa* #893949) or ¼ or 1X MIC of meropenem (MEM; *P. aeruginosa* #889839). Against *A. baumannii*, FOS was shown to be synergistic at 24h when tested at 0.5, 1 and 2X MIC with MEM (1X MIC).

Conclusions: The combination of two cell wall active agents, FOS plus selected β-lactams, provided enhanced killing and *in vitro* synergy against concerning GNB.

Character count: 2199 (2200 allowed)

Key words: fosfomycin, Synergy, kill-kinetics, Gram-negative

Track CPHM02